|
Market Closed -
Euronext Paris
11:55:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 73.10 EUR | +0.63% |
|
+1.39% | -11.63% |
| 10-01 | Healthcare Stocks Among Top Losers -- Healthcare Roundup | DJ |
| 10-01 | US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season | RE |
| Market Cap | 87.58B 98.6B 81.9B 74.63B 141B 9,494B 142B 991B 384B 4,835B 370B 362B 15,529B | P/E 2026 * |
11.6x | P/E 2027 * | 10.1x |
|---|---|---|---|---|---|
| Enterprise Value | 99.04B 112B 92.62B 84.4B 159B 10,736B 161B 1,120B 434B 5,468B 419B 410B 17,562B | EV / Sales 2026 * |
2.08x | EV / Sales 2027 * | 1.89x |
| Free-Float |
88.34% | Yield 2026 * |
5.82% | Yield 2027 * | 6.15% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| SAN | Real-time | |
CBOE
| SAN | Real-time | |
|
Tradegate
| SNW | Real-time | |
|
Xetra
| SNW | Delayed | |
|
London S.E.
| 0O59 | Delayed | |
|
Börse Stuttgart
| SNW | Delayed | |
|
Boerse Muenchen
| SNW | Real-time | |
|
Deutsche Boerse AG
| SNW | Delayed | |
|
Wiener Boerse
| SANO | End-of-day quote | |
|
Borsa Italiana
| 1SAN | End-of-day quote | |
|
OTC Markets
| SNYNF | Delayed | |
|
Mexican S.E.
| SAN1 N | End-of-day quote | |
|
Bulgaria S.E.
| SNW | End-of-day quote | |
|
Swiss Exchange
| SAN | Delayed | |
|
CBOE
| 0O59 | Real-time |
Last Transcript: Sanofi
| 1 day | +0.63% | ||
| 1 week | +1.39% | ||
| Current month | +0.63% | ||
| 1 month | -4.89% | ||
| 3 months | +0.07% | ||
| 6 months | -11.79% | ||
| Current year | -11.63% |
| 1 week | 71.22 |  | 75.3 |
| 1 month | 70.96 | | 77.89 |
| Current year | 70.96 | | 84.97 |
| 1 year | 70.96 | | 91.15 |
| 3 years | 70.96 | | 110.88 |
| 5 years | 70.96 | | 110.88 |
| 10 years | 62.88 | | 110.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 2026-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 65 | 2020-04-27 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/20/26 | Buy | Chief Executive Officer | 1,506 | 0.0001% | ||
| 8/20/26 | Buy | Head of Human Resources | 54 | 0.0000% | ||
| 8/20/26 | Buy | Executive/Senior Manager | 840 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.63% | +1.39% | -14.18% | -27.97% | 98.6B | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,025B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 623B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 459B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 355B | |
| -0.03% | -3.96% | +23.63% | +39.35% | 336B | |
| -1.58% | -0.76% | +13.50% | +25.77% | 270B | |
| -2.02% | -2.97% | -3.25% | +8.38% | 247B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 220B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 183B | |
| Average | -1.20% | -1.28% | +23.31% | +48.81% | 381.68B | |
| Weighted average by Cap. | -1.19% | -1.81% | +29.36% | +66.78% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.65B 53.65B 44.56B 40.61B 76.45B 5,165B 77.5B 539B 209B 2,631B 201B 197B 8,449B | 50.64B 57.02B 47.36B 43.16B 81.25B 5,490B 82.37B 573B 222B 2,796B 214B 209B 8,980B |
| Net income | 7.48B 8.42B 6.99B 6.37B 12B 811B 12.16B 84.61B 32.75B 413B 31.61B 30.93B 1,326B | 8.89B 10B 8.31B 7.57B 14.26B 963B 14.45B 101B 38.92B 491B 37.56B 36.75B 1,576B |
| Net Debt | 11.46B 12.91B 10.72B 9.77B 18.39B 1,243B 18.64B 130B 50.2B 633B 48.46B 47.41B 2,033B | 8.34B 9.39B 7.8B 7.1B 13.37B 904B 13.56B 94.31B 36.51B 460B 35.24B 34.47B 1,478B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-01 | €73.10 | +0.63% | 3,606,752 |
| 26-09-30 | €72.64 | +1.64% | 3,063,193 |
| 26-09-29 | €71.47 | -0.74% | 2,001,452 |
| 26-09-28 | €72.00 | +0.29% | 1,657,255 |
| 26-09-25 | €71.79 | -0.43% | 1,755,708 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
Select your edition
All financial news and data tailored to specific country editions
